HSBC Holdings plc HSBA.L
Composite 59/100; the shares have moved about 27% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 16/100 — a strong mark against it.
Income ranks 88/100 — a strong point in its favour. Momentum ranks 86/100 — a strong point in its favour. Valuation ranks 84/100 — a strong point in its favour.
Growth ranks 16/100 — a strong mark against it. Balance-sheet strength ranks 42/100 — a slight mark against it.
What the company does HSBC Holdings plc is a global diversified bank operating through four segments: Hong Kong, UK, Corporate and Institutional Banking, and International Wealth and Premier Banking. It provides retail banking, wealth management, commercial banking, transaction banking, and capital markets services worldwide.
Key financials HSBC reports ROE of 11.6%, ROA of 0.7%, and net margins of 35.0%. Revenue and EPS growth stand at 3.3% and 2.6%, respectively. The dividend yield is 4.8% with a payout ratio of 60.8%. Valuation metrics include a forward P/E of 12.18 and P/B of 1.80.
Stock health Sideravia scores HSBC an overall 57.4, with Valuation at 72.8 and Momentum at 79.3, indicating attractive valuation and positive momentum. The stock is 2.65% below its 52-week high, with RSI(14) at 68.90.
Price vs fair value HSBC trades at a **PREMIUM** of 6.51% versus the 12-month analyst target of 1447.01 and at a **discount** of 10.70% versus the fair-value estimate of 1713.43. - Recent restructuring costs of $300M to exit Australia’s retail business may weigh on near-term earnings (MT Newswires). - HSBC’s cautious stance on AI reinvestment and overspending fears may limit growth upside (Investing.com). - Simply Wall St. notes the stock may be a bargain on fair value but fully priced on earnings.
Looking forward Forward P/E of 12.18 and PEG of 0.29 suggest undemanding valuation, while dividend yield of 4.8% supports income appeal. Strategic divestitures, such as the $2.09B sale of its Singapore insurance unit, may reshape capital allocation. Analysts highlight valuation attractiveness but flag earnings sensitivity to restructuring and growth reinvestment.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.